Atyr Pharma Return on Equity

Atyr Pharma (LIFE) currently reports a ROE of -124.64%. That is below the Healthcare sector average of 20.86%. Use the charts on this page to explore Atyr Pharma's ROE history and peer comparisons.

Atyr Pharma's ROE of -124.64% is lower than the Healthcare sector average of 20.86%. That is roughly 697.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Atyr Pharma's current -124.64% should be judged against Healthcare norms (sector average: 20.86%) and against LIFE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -124.64%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 20.86%. From there, open related valuation or income-statement pages for Atyr Pharma, and consider following LIFE for alerts when major investors trade the stock.

Atyr Pharma is classified in the Healthcare sector. On ROE, it currently shows -124.64% versus a sector average near 20.86%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIFE with unrelated industries.